Because CD39 expression by CD8+ T cells in these tumors appears to be associated with tumor-reactivity, we hypothesize that patients with higher frequencies or densities of these cells should respond better to checkpoint blockade immunotherapy. This evidence concerns the gene CD8A and neoplasm.